-
VERO Biotech Secures $50 Million Funding from Runway Growth Capital
-
FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space
-
VERO Biotech Receives Funding from MVM Partners to Accelerate Growth
-
Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine
-
VERO Biotech Commits to Atlanta Healthcare Providers, Patients and Workforce During COVID-19 Pandemic
-
FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
-
VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated with GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
-
VERO Biotech, Leaders in the Development of Innovative Technologies for Inhaled Nitric Oxide Delivery, to Present at Biotech Showcase 2020
-
VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide
-
Biotech Firm Opens 15,585 SF Headquarters at Georgia Tech’s Technology Enterprise Park in Atlanta
Contact Info
387 Nerem Street NW, Suite 125
Atlanta, Georgia 30313
Product Inquiries
To report an adverse event, product questions or complaints, other safety-related information or technical support for a company product
877-337-4118
Quick Links
Medical Inquiries
For medical inquiries, click on the Request Form below.
Cigna Machine Readable Files
This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of- network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers
Indication & Safety Information
GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
- GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
- Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
- Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
- In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
- Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
- Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
- See package insert for additional Important Safety Information.